×
About 653 results

ALLMedicine™ Parathyroid Carcinoma Center

Research & Reviews  216 results

Fine-tuned continuous renal replacement therapy with calcium-free dialysate to manage s...
https://doi.org/10.1186/s40001-022-00715-x 10.1177/0885066613507530 10.1097/MOO.0000000000000234 10.1136/bmj.h2723 10.1097/MAT.0000000000000186 10.1097/MAT.0b013e31817dc3be 10.1136/bcr-2017-223772 10.1159/000188907
European Journal of Medical Research; Scheen M, Nowak G et. al.

Jun 9th, 2022 - Malignancy-related hypercalcemia is a leading cause of hypercalcemia among hospitalized patients that carries poor prognosis. Parathyroid carcinoma is a rare form of primary hyperparathyroidism that may be associated with PTH dependent hypercalcem...

Primary Hyperparathyroidism Imaging
https://emedicine.medscape.com/article/390728-overview

May 31st, 2022 - Practice Essentials Primary hyperparathyroidism affects approximately 0.3% of the population, with about 90% of patients having a single parathyroid adenoma and 10% having multigland hyperplasia or multiple adenomas. In rare cases, patients are fo...

Primary Hyperparathyroidism Imaging
https://emedicine.medscape.com/article/390728-print

May 31st, 2022 - Primary hyperparathyroidism affects approximately 0.3% of the population, with about 90% of patients having a single parathyroid adenoma and 10% having multigland hyperplasia or multiple adenomas. In rare cases, patients are found to have parathyr...

Primary Hyperparathyroidism Imaging
http://emedicine.medscape.com/article/390728-overview

May 31st, 2022 - Practice Essentials Primary hyperparathyroidism affects approximately 0.3% of the population, with about 90% of patients having a single parathyroid adenoma and 10% having multigland hyperplasia or multiple adenomas. In rare cases, patients are fo...

Intrathyroidal Parathyroid Carcinoma: Case Report and Literature Review.
https://doi.org/10.1177/01455613221093729
Ear, Nose, & Throat Journal; Daniel H, Pillutla P et. al.

Apr 12th, 2022 - Intrathyroidal parathyroid carcinoma (PC) is a rare malignancy that is usually difficult to diagnose. We present a case of a 31-year-old male with a history of hyperparathyroidism who was found to have intrathyroidal PC upon review of immunostains...

see more →

Guidelines  1 results

2009 EANM parathyroid guidelines.
https://doi.org/10.1007/s00259-009-1131-z
European Journal of Nuclear Medicine and Molecular Imaging; Hindié E, Ugur O et. al.

May 28th, 2009 - The present guidelines were issued by the Parathyroid Task Group of the European Association of Nuclear Medicine. The main focus was imaging of primary hyperparathyroidism. Dual-tracer and single-tracer parathyroid scintigraphy protocols were disc...

see more →

Drugs  32 results see all →

Clinicaltrials.gov  7 results

F-18 PSMA for Localization of Parathyroid Adenoma
https://clinicaltrials.gov/ct2/show/NCT05299632

Apr 4th, 2022 - Hyperparathyroidism is an increasingly significant medical and public health condition in the United States. In the past two decades, the incidence of hyperparathyroidism has increased 300%, and currently, the disease affects at least 30,000 new p...

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
https://clinicaltrials.gov/ct2/show/NCT03280264

May 27th, 2021 - To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
https://clinicaltrials.gov/ct2/show/NCT00195936

Jan 19th, 2021 - X-linked hypophosphatemic rickets (XLH) is an X-linked dominant genetic disorder. Common findings are low serum phosphate and inadequate 1,25(OH)2 vitamin D production. It is generally believed that the primary defect in XLH is impaired renal tubu...

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
https://clinicaltrials.gov/ct2/show/NCT04106843

Sep 7th, 2020 - PRIMARY OBJECTIVE: I. Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 determined by Ia. Computed tomography (CT) or Ib. Magnetic resonance imaging (MRI). SECONDARY OBJECTIVES: I. To estimate progression-f...

Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
https://clinicaltrials.gov/ct2/show/NCT03039439

Jan 13th, 2020 - PRIMARY OBJECTIVES: I. To determine the differences in clinical behavior and immunohistochemical (IHC) biomarkers between parathyroid carcinoma (PC), atypical neoplasm (AN) and parathyroid adenoma (PA). II. To determine which potential genes can b...

see more →

News  5 results

A 38-Year-Old Man With Back and Side Pain: Osmosis USMLE Study Question
https://www.medscape.com/viewarticle/899201_2

Feb 21st, 2020 - Nephrocalcinosis is a condition characterized by the calcification of the renal tubules that leads to renal insufficiency. This occurs via metastatic calcification, which means that calcium is deposited in normal tissues, rather than those that ha...

Primary hyperparathyroidism: Labs to order, Tx to consider
https://www.mdedge.com/familymedicine/article/178451/endocrinology/primary-hyperparathyroidism-labs-order-tx-consider
MDedge Family Medicine; Padmaja Sanapureddy, MD, Vishnu Vardhan Garla, MD et. al.

Nov 1st, 2018 - Since the advent of multichannel serum chemistry screening in the 1970s, large numbers of asymptomatic cases of primary hyperparathyroidism (PHPT) have been discovered. The clinical spectrum of the disease has changed from the classic “moans, groa.

Cinacalcet Trials Halted Due to Pediatric Death
https://www.medscape.com/viewarticle/779918

Feb 26th, 2013 - The US Food and Drug Administration (FDA) today announced that it has halted all pediatric clinical trials of cinacalcet (Sensipar, Amgen), a calcium-lowering drug, after the recent death of a 14-year-old patient in a study. The FDA decision to st...

A 45-Year-Old Man With a Maxillary Mass and Hypercalcemia
https://www.medscape.com/viewarticle/468503_3

Feb 28th, 2005 - Discussion The case of this unfortunate patient presents several points of interest. Brown tumors are rare, seen in fewer than 5% of patients with primary hyperparathyroidism today. Early detection of hypercalcemia due to rapid multichannel bioche...

see more →